HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hirai, T. Articles by Slutsky, A. S. Search for Related Content PubMed PubMed Citation Articles by Hirai, T. Articles by Slutsky, A. S.

The Annals of Thoracic Surgery, Vol 58, 496-501, Copyright © 1994 by The Society of Thoracic Surgeons

ARTICLES

A short course of FK506 can induce limited donor-specific graft acceptance

T Hirai, TK Waddell, KN DeCampos, CG Compeau, H Wada, S Hitomi, GA Patterson and AS Slutsky
Department of Thoracic Surgery, Kyoto University, Japan.

To examine the hypothesis that a short course of FK506 would induce permanent graft acceptance after lung transplantation, left lung allotransplantation was performed in 14 mongrel dogs. In group 1 (control; n = 3), no immunosuppressive agent was given. In group 2 (n = 7), FK506 (1.2 mg/kg intramuscularly) was given on posttransplantation days 0, 1, and 2. In group 3 (n = 4), FK506 was given at the same dose on posttransplantation days 0, 1, and 2 as well as on days 29 and 30. Allograft function was evaluated by temporarily occluding the right pulmonary artery. A mixed lymphocyte reaction study was performed preoperatively and monthly thereafter. Control lungs were all rejected within 8 days. Group 2 dogs showed improved survival, with a median survival of 49.5 days. One dog in group 2 lived more than 400 days after transplantation. The mixed lymphocyte reaction data suggests that some donor-specific unresponsiveness occurs, which lasts for only a limited time. Supplemental doses of FK506 did not significantly improve survival (median, 74 days). The whole blood level of FK506 was 17.7 +/- 3.98 ng/mL on day 15; however, on day 29 the FK506 level was almost undetectable. We conclude that a 3-day course of 1.2 mg/kg of FK506 can induce donor-specific graft acceptance, but this acceptance is not permanent.

This article has been cited by other articles:

				R. Nakanishi and K. Yasumoto Multiglycosidorum tripterygii versus Tacrolimus for rat tracheal allografts Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 588 - 593. [Abstract] [Full Text] [PDF]